


1 **Supplemental data for ‘Alternative lipid synthesis in response to phosphate limitation**  
2 **promotes antibiotic tolerance in Gram-negative ESKAPE pathogens’**


3  
4 Roberto Jhonatan Olea-Ozuna<sup>a</sup>, Melanie J. Campbell<sup>b</sup>, Samantha Y. Quintanilla<sup>a</sup>, Sinjini Nandy<sup>a</sup>,  
5 Jennifer S. Brodbelt<sup>b</sup>, and Joseph M. Boll<sup>a, #</sup>

6  
7 **Supplementary Figures**




9  
10  
11 **Figure S1: *Escherichia coli* (*Ec*) and *Acinetobacter baumannii* (*Ab*) lipid composition after**  
12 **growth in complex media.** A. Strains were grown in complex media (LB broth) in the presence  
13 of <sup>32</sup>P-orthophosphoric acid until mid-logarithmic growth phase. Cells were collected and total  
14 lipids were extracted using the Bligh and Dyer method and separated using 2-dimensional thin-  
15 layer chromatography. Labelled lipids include anionic cardiolipin (CL) and phosphatidylglycerol  
16 (PG), aminolipids phosphatidylethanolamine (PE) and lyso-PE (LPE), and unknown phospholipid  
17 1 (UPL1). B. PG, PE, CL and LPE chemical structures. Head groups are red, the glycerol backbone  
18 is blue, and fatty acids are black.

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31



32  
 33  
 34 **Figure S2: Effect of phosphate availability on growth, cell morphology, and LOS production.**  
 35 **A.** *A. baumannii* ATCC 17978 was cultured in minimal medium containing either excess (1 mM)  
 36 or limiting (50 μM) phosphate for 24 hours. **B.** Phase-contrast images of *A. baumannii* grown  
 37 under these conditions, captured during the exponential phase. Scalebar is 10 μm. **C.** Cell length  
 38 and area were quantified for each population ( $n \geq 150$ ) using ImageJ software. Each point  
 39 represents an individual cell. The experiment was repeated twice, and one representative dataset  
 40 was reported. Significance testing conducted using Student *t* test with two-tailed distribution  
 41 assuming equal variance. \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . **D.** Proteinase K-treated whole-cell lysate  
 42 from wild-type *A. baumannii* strains ATCC 17978, ATCC 19606, and AB5075, as well as from  
 43 aminolipid-deficient mutants grown under excess (1mM) or limiting (50 μM) phosphate  
 44 conditions. The LOS samples were separated using SDS-PAGE and stained using Pro-Q Emerald  
 45 300.

46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55



57

58 **Figure S3: Thin-layer chromatography of aminolipids in *Acinetobacter* strains.** A. To produce  
 59 samples for MS analysis, total lipids were separated using thin-layer chromatography and scraped  
 60 from the plate, extracted using the Bligh and Dyer method, and run alongside lipid controls.  
 61 Extractions resulted in isolation of U1 & U2, U1, or U2. Lipids were stained with ninhydrin to  
 62 visualize aminolipids. Specific lipids are labelled: PE, phosphatidylethanolamine; U1, unknown  
 63 lipid 1; U2, unknown lipid 2. B. Total lipids were grown in minimal medium supplemented with  
 64 excess (1 mM) or limiting (50 μM) phosphate conditions from indicated *Acinetobacter* strains.  
 65 Total lipids were spotted on thin-layer chromatography and separated based on hydrophobicity.  
 66 Plates were stained with ninhydrin to visualize aminolipids. Specific lipids are labelled: PE,  
 67 phosphatidylethanolamine; OL, ornithine lipid; LL, lysine lipid.

68

69

70

71

72

73

74

75

76

77

78

79

80

81


82

83

84


85

86



87  
 88 **Figure S4: *olsB* and *olsA* are required for ornithine and lysine lipid biosynthesis in *A.***  
 89 ***baumannii*.** **A.** 2D thin-layer chromatography lipid analysis in ATCC 19606 wild type and the  
 90  $\Delta olsB$  mutant strain after growth in limiting (50  $\mu$ M) phosphate concentrations. Lipids were  
 91 stained with sulfuric acid. **B.** Analysis in AB5075 wild type and transposon (*Tn101*) mutant strains  
 92 after growth in limiting (50  $\mu$ M) phosphate concentrations. Specific lipids are labelled: PE,  
 93 phosphatidylethanolamine; PG, phosphatidylglycerol; CL, cardiolipin; OL, ornithine lipid; LL,  
 94 lysine lipid. OL and LL aminolipids are labelled in red. **C.** Phase-contrast images of *A. baumannii*  
 95 strain ATCC 17978 grown under phosphate limiting conditions, captured during exponential phase  
 96 growth. Scalebar is 10  $\mu$ m. **D.** Cell length and area of strain ATCC 17978 were quantified for each  
 97 population ( $n \geq 150$ ) using ImageJ software. Each point represents an individual cell.  
 98 Significance testing conducted using Student *t* test with two-tailed distribution assuming equal  
 99 variance. ns = not significant. **E.** Optical density (OD<sub>600</sub>) measurements of *A. baumannii* strains  
 100 grown in 50  $\mu$ M phosphate over 24 h.

101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111



113  
 114 **Figure S5: Aminolipid formation promotes *A. baumannii* tolerance to colistin.** Growth  
 115 (OD<sub>600</sub>) of *A. baumannii* ATCC 17978 strains was measured at 37 °C in minimal medium with  
 116 limiting phosphate (A) or excess phosphate (B), and in the presence of colistin at concentrations  
 117 of 1, 2.5, or 5 mg/L.

118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139

140  
141  
142  
143

**Supplementary Tables**  
**Please See the Excel Spreadsheet for Tables S1-3**  
**Table S4: Strains and plasmids used in this study.**

Strain or Plasmid	Description	Reference or Source
<b><u>Strains</u></b>		
<i>A. baumannii</i> ATCC 17978	Wild type	(1)
<i>A. baumannii</i> ATCC 19606	Wild type	(2)
<i>A. baumannii</i> AB5075	Wild type	(3)
<i>A. baumannii</i> AYE	Wild type	(4)
<i>A. baylyi</i> ADP1	Wild type	(5)
<i>P. aeruginosa</i> PAO1	Wild type	(6)
<i>K. pneumoniae</i> KPNIH1	Wild type	(7)
<i>E. cloacae</i> ATCC 13047	Wild type	(8)
<i>A. baumannii</i> ATCC 17978	$\Delta olsB$ (AIS_0889)::deletion	This study
<i>A. baumannii</i> ATCC 17978	$\Delta phoR$ (AIS_3376)::deletion	This study
<i>A. baumannii</i> ATCC 19606	$\Delta olsB$ (HMPREF0010_01383)::deletion	This study
<i>A. baumannii</i> AB5075	$\Delta olsB$ (ABUW_3039)::tn101	(9)
<i>A. baumannii</i> AB5075	$\Delta olsA$ (ABUW_0502)::tn101	(9)
<i>A. baumannii</i> AB5075	$\Delta phoR$ (ABUW_0105)::tn26	(9)
<i>E. coli</i> W3110	Wild type, F- $\lambda$ -, <i>rph-1</i> IN ( <i>rrnD</i> , <i>rrnE</i> )I	(10)
<i>E. coli</i> DH5 $\alpha$	recA1, $\phi$ 80 <i>lacZ</i> ΔM15, host for cloning	(11)
<b><u>Plasmids</u></b>		
pAT03	pMMB67EH with FLP recombinase, Tet <sup>R</sup>	(12)
pAT04	pMMB67EH with REC <sub>Ab</sub> system, Tet <sup>R</sup>	(12)
pKD4	Kan <sup>R</sup>	(13)

pMMB67EHKn	pMMB67EH with the Kan <sup>R</sup> gene from pKD4 inserted into the PvuI site, Kan <sup>R</sup>	(14)
pROB01	pMMB67EHKn carrying <i>olsB</i> ( <i>AIS_0889</i> )	This study
pROB02	pMMB67EHKn carrying <i>phoR</i> ( <i>AIS_3376</i> )	This study

144  
145  
146

**Table S5: Primers used in this study.**

Oligo Name	Sequence (5' to 3')
<b>Deletion Primers</b>	
17978 <i>olsB</i> Ab Kan FRT 5'	AGTGGGTGTCACTAGGAGCGTTCATTATGCTGGAAAA TTAATCAATATCGCCAAACCTGGACTTTACCTTTAAAT CGCCATAAGGCTAACAATCAAACACAATTCCGCTTGA ATGGGTTGATAGCGATTGTGTAGGCTGGAGCTGCTTCG
17978 <i>olsB</i> Ab Kan FRT 3'	TTGTTATTACAAACGAAGTGGCAATTTTATTCACTTCT AAAAATACAAAGTAATCGAGACAGTTAAATTCAGCATC AAAGAAAGCATCTTTAGATAATTTAGACTGCATACTCA AATACATTTGATATCCTCCTTAGTTCCTATTCCG
17978 <i>olsB</i> Ab confirm 5'	GTGGTGTGTGAGCGCACATATTG
17978 <i>olsB</i> Ab confirm 3'	GCCTTGAGTCGCCTTACGAATATG
17978 <i>phoR</i> Ab Kan FRT 5'	CGTTTGCTAAACAAGATTTACGACTTTTATTATTTTCT GATTATTGCAGGTTTAGTCGTTTAGGAATTGGGTATTT CTGGAGCTGTATTTTATTGCCTTTGTGGTGTTTTTTACA CTTCAGAGCGATTGTGTAGGCTGGAGCTGCTTCG
17978 <i>phoR</i> Ab Kan FRT 3'	ATGTTATAGAGTCTTTCTTTTGGAAAACTGCGGTAAAG GTTGATCCTTCATTTTCTTTAGATTGCACATCTAAGTAG GCGCCGTGTTGCATGAGTACATGTTTTACAATCGCCAAG CCTAAACCATATCCTCCTTAGTTCCTATTCCG
17978 <i>phoR</i> Ab 5' confirm	GGACCAACAGAATACCGTCTGCTTG
17978 <i>phoR</i> Ab 3' confirm	GATGGTGGAGATCATCGTGATGCAC
<b>Complementation Primers</b>	
17978 <i>olsB</i> Ab KpnI 5'	CGCGGTACCATGCTGGAAAATTTAATCAATATCGC
17978 <i>olsB</i> Ab Sall 3'	CGCGTCGACTTATCGCTGAGCCATTTTGTTT
17978 <i>phoR</i> Ab SacI 5'	CGCGAGCTCATGTATGAACCCTACCCCGTCC
17978 <i>phoR</i> Ab BamHI 3'	CGCGGATCCTTAAAGTCATGTTATAGAGTCTTTCTTTGG
<b>Transposon mutant primers</b>	
AB5075 <i>olsB::tn101</i> 5'	CGACACAAGAAGTTGACCGTTTAATCG

confirm	
AB5075 <i>olsB</i> :: <i>tn101</i> 3' confirm	CAATTGGTGATTCAACTGCAGACTGG
AB5075 <i>olsA</i> :: <i>tn101</i> 5' confirm	GCTCAAGAATATCTGCACCAGCTGAC
AB5075 <i>olsA</i> :: <i>tn101</i> 3' confirm	GGATGAGCTGGCAACTAAAGCG
AB5075 <i>phoR</i> :: <i>tn26</i> 5' confirm	GTCTGGATGCTGGTGCAGATGAC
AB5075 <i>phoR</i> :: <i>tn26</i> 3' confirm	GGTGCCGACTGTACCGTTAATG

147

148

149

150

151

## 152 References

153 1. Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative  
154 species (genus *Acinetobacter*). *J Bacteriol.* 1968 May;95(5):1520–41.

155 2. Bouvet PJM, Grimont PAD. Taxonomy of the Genus *Acinetobacter* with the Recognition of  
156 *Acinetobacter baumannii* sp. nov., *Acinetobacter haemolyticus* sp. nov., *Acinetobacter*  
157 *johnsonii* sp. nov., and *Acinetobacter junii* sp. nov. and Emended Descriptions of  
158 *Acinetobacter calcoaceticus* and *Acinetobacter lwoffii*. *International Journal of Systematic*  
159 *and Evolutionary Microbiology.* 1986;36(2):228–40.

160 3. Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, et al. AB5075,  
161 a Highly Virulent Isolate of *Acinetobacter baumannii*, as a Model Strain for the Evaluation of  
162 Pathogenesis and Antimicrobial Treatments. *mBio.* 2014 Jul 1;5(3):e01076-14.

163 4. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics  
164 of multidrug resistance in *Acinetobacter baumannii*. *PLoS Genet.* 2006 Jan;2(1):e7.

165 5. Barbe V, Vallenet D, Fonknechten N, Kreimeyer A, Oztas S, Labarre L, et al. Unique features  
166 revealed by the genome sequence of *Acinetobacter* sp. ADP1, a versatile and naturally  
167 transformation competent bacterium. *Nucleic Acids Res.* 2004;32(19):5766–79.

168 6. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warren P, Hickey MJ, et al. Complete  
169 genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature.*  
170 2000 Aug 31;406(6799):959–64.

171 7. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, NISC Comparative Sequencing Program  
172 Group, Henderson DK, et al. Tracking a hospital outbreak of carbapenem-resistant *Klebsiella*  
173 *pneumoniae* with whole-genome sequencing. *Sci Transl Med.* 2012 Aug 22;4(148):148ra116.



- 174 8. Ren Y, Ren Y, Zhou Z, Guo X, Li Y, Feng L, et al. Complete genome sequence of  
175 *Enterobacter cloacae* subsp. *cloacae* type strain ATCC 13047. *J Bacteriol.* 2010  
176 May;192(9):2463–4.
- 177 9. Gallagher LA, Ramage E, Weiss EJ, Radey M, Hayden HS, Held KG, et al. Resources for  
178 Genetic and Genomic Analysis of Emerging Pathogen *Acinetobacter baumannii*. *J Bacteriol.*  
179 2015 Jun;197(12):2027–35.
- 180 10. Bachmann BJ. Pedigrees of some mutant strains of *Escherichia coli* K-12. *Bacteriol Rev.* 1972  
181 Dec;36(4):525–57.
- 182 11. Hanahan D. Studies on transformation of *Escherichia coli* with plasmids. *J Mol Biol.* 1983 Jun  
183 5;166(4):557–80.
- 184 12. Tucker AT, Nowicki EM, Boll JM, Knauf GA, Burdis NC, Trent MS, et al. Defining Gene-  
185 Phenotype Relationships in *Acinetobacter baumannii* through One-Step Chromosomal Gene  
186 Inactivation. *mBio.* 2014 Aug 29;5(4).
- 187 13. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli*  
188 K-12 using PCR products. *Proceedings of the National Academy of Sciences.* 2000 Jun  
189 6;97(12):6640–5.
- 190 14. Kang KN, Kazi MI, Biboy J, Gray J, Bovermann H, Ausman J, et al. Septal Class A Penicillin-  
191 Binding Protein Activity and Id-Transpeptidases Mediate Selection of Colistin-Resistant  
192 Lipooligosaccharide-Deficient *Acinetobacter baumannii*. *mBio.* 2021 Jan 5;12(1):e02185-20.